Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

40.82
-0.3800-0.92%
Post-market: 41.000.1800+0.44%17:30 EDT
Volume:1.39M
Turnover:56.59M
Market Cap:8.43B
PE:-14.49
High:41.28
Open:40.96
Low:39.91
Close:41.20
52wk High:45.42
52wk Low:14.58
Shares:206.40M
Float Shares:89.57M
Volume Ratio:1.30
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:11.46
PE(LYR):-14.73

Loading ...

Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit

Reuters
·
Apr 24

Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential

TIPRANKS
·
Apr 07

Immunovant CEO Eric Venker disposes of common shares worth $8.5 million

Reuters
·
Apr 04

Sector Update: Health Care Stocks Softer Thursday Afternoon

MT Newswires Live
·
Apr 03

Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback

TIPRANKS
·
Apr 02

Immunovant price target lowered to $50 from $52 at Leerink

TIPRANKS
·
Apr 02

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks

Reuters
·
Apr 02

Immunovant reports batoclimab clinical studies missed primary endpoint

TIPRANKS
·
Apr 02

Immunovant Shares Fall 16% Premarket After Co's Treatment for Eye Disease Fails Late-Stage Trial

THOMSON REUTERS
·
Apr 02

Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease

Reuters
·
Apr 02

Immunovant Inc - to Review Future Plans for Batoclimab Development With Hanall Biopharma

THOMSON REUTERS
·
Apr 02

Immunovant Inc - Topline Data From Imvt-1402 Graves’ Disease Studies Expected in 2027

THOMSON REUTERS
·
Apr 02

Immunovant Inc - Batoclimab in Ted Shows No New Safety Signals in Phase 3 Studies

THOMSON REUTERS
·
Apr 02

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)

THOMSON REUTERS
·
Apr 02

Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)

TIPRANKS
·
Apr 01

Bernstein initiates Immunovant with a Market Perform, $28 price target

TIPRANKS
·
Mar 20

Roivant Sciences President and Immunovant CEO Eric Venker disposes of USD 5.65 million in common shares

Reuters
·
Mar 20